Research Grade Repaglinide Meglitinide Raw Powder
TDS
135062-02-1
Reagent Grade
99%
shenzhen
QY
10mg
2027-06-16
Retatrutide,Tirzepatide,Semaglutide,GHK-CU
-
Product Description
-
Seller Information
-
DescriptionECHEMI Editorial ReferenceWhite crystalline powder, odorless. Crystallization from ethanol-water (2:1), melting point 126-128℃. Crystallization from neutral water, melting point 130~131℃. [α]D20+6.97℃ (C=0.975, methanol); [α]D20+7.45°(C=1.06, methanol). Acute toxicity LD50. Rat (g/kg): > 1 oral.
Solid
Repaglinide is a member of piperidines.|Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Repaglinide is extensively metabolized in the liver and excreted in bile. Repaglinide metabolites do not possess appreciable hypoglycemic activity. Approximately 90% of a single orally administered dose is eliminated in feces and 8% in urine.|Repaglinide is a Glinide. The mechanism of action of repaglinide is as a Potassium Channel Antagonist.|Repaglinide is a benzoic acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of type 2 diabetes. Repaglinide has been linked to rare instances of clinically apparent acute liver injury.|Repaglinide is a nonsulfonylurea insulin secretagogue belonging to the melgitinide class with hypoglycemic activity. Repaglinide is rapidly absorbed and has a rapid onset and short duration of action. This agent is metabolized in the liver by CYP2C8 and CYP3A4 and its metabolites are excreted in the bile. Repaglinide has a half-life of one hour.Certificates-
TDS
Basic Info-
Product Name:
Repaglinide
Other Name:Benzoic acid,2-ethoxy-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]-;Benzoic acid,2-ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]-,(S)-;2-Ethoxy-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid;Repaglinide;AG-EE 623ZW;Prandin;NovoNorm;(S)-(+)-2-Ethoxy-4-[[[N-[1-(2-piperidinophenyl)-3-methylbutyl]amino]carbonyl]methyl]benzoic acid;AGEE 623;Novolon;Eurepa;(S)-(+)-Repaglinide;GlucoNorm;Europa 0.5;Europa 1;(S)-2-Ethoxy-4-[2-[[3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid;Enyglid
CAS No.:135062-02-1
Molecular Formula:C27H36N2O4
InChIKeys:InChIKey=FAEKWTJYAYMJKF-QHCPKHFHSA-N
Molecular Weight:452.59
Exact Mass:452.59
EC Number:1312995-182-4
UNII:668Z8C33LU
NSC Number:759893
DSSTox ID:DTXSID3023552
NCI Thesaurus Code:C47703
ATC Code:A10BX02|A - Alimentary tract and metabolism
HScode:2933399090
Categories:
Characteristics-
PSA:
78.9
XLogP3:5.9
Appearance:white solid
Density:1.137±0.06 g/cm3(Predicted)
Melting Point:132 °C
Boiling Point:672.9°C at 760 mmHg
Flash Point:360.8ºC
Refractive Index:1.567
Water Solubility:DMSO: 34 mg/mL
Storage Conditions:2-8°C
Vapor Pressure:5E-19mmHg at 25°C
Toxicity:LD50 orally in rats: >1 g/kg (Grell)
Specific rotation:D20 +6.97° (c = 0.975 in methanol); D20 +7.45° (c = 1.06 in methanol)
Hazard IdentificationClassification of the substance or mixture
Reproductive toxicity, Category 2
Reproductive toxicity, Additional category for effects on or via lactation
Hazardous to the aquatic environment, long-term (Chronic) - Category Chronic 3
GHS label elements, including precautionary statements
Pictogram(s)
Signal word Warning
Hazard statement(s) H361 Suspected of damaging fertility or the unborn child
H362 May cause harm to breast-fed children
H412 Harmful to aquatic life with long lasting effects
Precautionary statement(s) Prevention P203 Obtain, read and follow all safety instructions before use.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
P260 Do not breathe dust/fume/gas/mist/vapours/spray.
P263 Avoid contact during pregnancy and while nursing.
P264 Wash ... thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P273 Avoid release to the environment.
Response P318 IF exposed or concerned, get medical advice.
Storage P405 Store locked up.
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Retatrutide,Tirzepatide,Semaglutide,GHK-CU
-
Location:
Plot 1, No. 205 Tongbao Road, Jiangdong Subdistrict, Yiwu City, Jinhua City, Zhejiang Province
-
Payment Terms:
TT against B/L draft before shipment,100% TT in advance
-
Year of Establishment:
2026
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product